A Quick Look at Today's Ratings for Xencor(XNCR.US), With a Forecast Between $30 to $30
Analysts Offer Insights on Healthcare Companies: Ocular Therapeutix (OCUL), Xencor (XNCR) and GeneDx Holdings (WGS)
Piper Sandler Maintains Xencor(XNCR.US) With Buy Rating, Maintains Target Price $30
William Blair Initiates Xencor(XNCR.US) With Buy Rating
Xencor Analyst Ratings
Barclays Reaffirms Their Sell Rating on Xencor (XNCR)
Piper Sandler Maintains Xencor(XNCR.US) With Buy Rating, Maintains Target Price $30
J.P. Morgan Maintains Xencor(XNCR.US) With Buy Rating, Cuts Target Price to $23
Xencor Analyst Ratings
Wells Fargo Maintains Overweight on Xencor, Lowers Price Target to $33
RBC Capital Adjusts Xencor Price Target to $32 From $34, Maintains Outperform - Speculative Risk Rating
BMO Capital Maintains Xencor(XNCR.US) With Buy Rating, Maintains Target Price $34
A Quick Look at Today's Ratings for Xencor(XNCR.US), With a Forecast Between $30 to $38
Analysts Have Conflicting Sentiments on These Healthcare Companies: Iovance Biotherapeutics (IOVA), Xencor (XNCR) and Merus (MRUS)
Wedbush Cuts Price Target on Xencor to $31 From $38, Keeps Outperform Rating
BofA Securities Maintains Xencor(XNCR.US) With Buy Rating, Cuts Target Price to $30
Analysts Conflicted on These Healthcare Names: Xencor (XNCR) and Pfizer (PFE)
Bank of America Securities Remains a Buy on Xencor (XNCR)
Xencor Initiated at Overweight by Wells Fargo
Wells Fargo Initiates Xencor(XNCR.US) With Buy Rating, Announces Target Price $37